FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084243998> ?p ?o ?g. }

• W2084243998 endingPage "67" @default.
• W2084243998 startingPage "53" @default.
• W2084243998 abstract "Lyophilized protein formulations sometimes pose problems such as the formation of a cloudy solution upon reconstitution. Ampoule or vial breakage can also occur during the production processes of lyophilized pharmaceutical products. Various efforts have been made to overcome those difficult problems. In this study, we introduce a particular temperature program into the production process of a recombinant human Interleukin-11 (rhIL-11) lyophilized formulation containing sodium phosphates (Na2HPO4/NaH2PO4, pH 7.0) and glycine in an attempt to improve its dissolution properties and to prevent ampoule breakage from occurring. The formulation was pretreated by nucleating ice and maintaining the solution overnight at a temperature of −6 °C. The solution was then completely frozen at a lower temperature. This pretreatment proved successful in not only producing a lyophilized cake which readily disintegrated and dissolved in the reconstitution media, but also prevented ampoule breakage from occurring during the production processes. In contrast, a lyophilized cake produced without the pretreatment created a cloudy solution particularly when reconstituted using water for injection contaminated with aluminum (Al3+), although the solution became transparent within 20–30 min. The pretreatment induced the crystallization of sodium dibasic phosphate (Na2HPO4) in the freeze-concentrate whereas direct freezing without the pretreatment did not crystallize the salt. Thermal analyses (DSC and TMA) showed that amorphous sodium dibasic phosphate in the freeze-concentrate became crystallized upon heating, accompanied by an increase in volume, which probably caused the ampoule breakage that occurred without the pretreatment. Although power X-ray diffraction (PXRD) experiments suggested that, with or without the pretreatment, glycine assumed the β-form and sodium phosphate stayed amorphous in the final products, an electrostatic interaction between dibasic phosphate anions and rhIL-11, a highly cationic protein, would only exist in the lyophilized cake produced without the pretreatment. This interaction is highly likely because aluminum facilitates the formation of a cloudy solution upon reconstitution possibly by using the divalent anions which effectively reduce electrostatic repulsions between aluminum and the protein to form an aggregate structure that is not readily soluble. The pretreatment would circumvent the interaction by crystallizing the sodium salt before freezing creating a relatively soluble lyophilized cake that is much less sensitive to aluminum." @default.
• W2084243998 created "2016-06-24" @default.
• W2084243998 creator A5012993555 @default.
• W2084243998 creator A5024034303 @default.
• W2084243998 creator A5038895043 @default.
• W2084243998 creator A5082827459 @default.
• W2084243998 creator A5088861945 @default.
• W2084243998 date "2004-11-01" @default.
• W2084243998 modified "2023-09-26" @default.
• W2084243998 title "The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11)" @default.
• W2084243998 cites W1276324155 @default.
• W2084243998 cites W1508367957 @default.
• W2084243998 cites W1522964448 @default.
• W2084243998 cites W1547038479 @default.
• W2084243998 cites W1583308104 @default.
• W2084243998 cites W1778245994 @default.
• W2084243998 cites W1849496189 @default.
• W2084243998 cites W1978269358 @default.
• W2084243998 cites W1986397390 @default.
• W2084243998 cites W1995787669 @default.
• W2084243998 cites W1997834085 @default.
• W2084243998 cites W2007471767 @default.
• W2084243998 cites W2007897007 @default.
• W2084243998 cites W2021898875 @default.
• W2084243998 cites W2035340445 @default.
• W2084243998 cites W2040956027 @default.
• W2084243998 cites W2048199422 @default.
• W2084243998 cites W2061409649 @default.
• W2084243998 cites W2066662804 @default.
• W2084243998 cites W2073489998 @default.
• W2084243998 cites W2080842528 @default.
• W2084243998 cites W2105574859 @default.
• W2084243998 cites W2118024162 @default.
• W2084243998 cites W2166622100 @default.
• W2084243998 cites W280510079 @default.
• W2084243998 doi "https://doi.org/10.1016/j.ijpharm.2004.07.030" @default.
• W2084243998 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15501002" @default.
• W2084243998 hasPublicationYear "2004" @default.
• W2084243998 type Work @default.
• W2084243998 sameAs 2084243998 @default.
• W2084243998 citedByCount "12" @default.
• W2084243998 countsByYear W20842439982015 @default.
• W2084243998 countsByYear W20842439982018 @default.
• W2084243998 countsByYear W20842439982020 @default.
• W2084243998 countsByYear W20842439982023 @default.
• W2084243998 crossrefType "journal-article" @default.
• W2084243998 hasAuthorship W2084243998A5012993555 @default.
• W2084243998 hasAuthorship W2084243998A5024034303 @default.
• W2084243998 hasAuthorship W2084243998A5038895043 @default.
• W2084243998 hasAuthorship W2084243998A5082827459 @default.
• W2084243998 hasAuthorship W2084243998A5088861945 @default.
• W2084243998 hasConcept C122191521 @default.
• W2084243998 hasConcept C13965031 @default.
• W2084243998 hasConcept C142724271 @default.
• W2084243998 hasConcept C159985019 @default.
• W2084243998 hasConcept C178790620 @default.
• W2084243998 hasConcept C185592680 @default.
• W2084243998 hasConcept C188027245 @default.
• W2084243998 hasConcept C192562407 @default.
• W2084243998 hasConcept C203036418 @default.
• W2084243998 hasConcept C2779015675 @default.
• W2084243998 hasConcept C2780742167 @default.
• W2084243998 hasConcept C28845197 @default.
• W2084243998 hasConcept C43617362 @default.
• W2084243998 hasConcept C71924100 @default.
• W2084243998 hasConcept C77281830 @default.
• W2084243998 hasConcept C84199377 @default.
• W2084243998 hasConcept C88380143 @default.
• W2084243998 hasConceptScore W2084243998C122191521 @default.
• W2084243998 hasConceptScore W2084243998C13965031 @default.
• W2084243998 hasConceptScore W2084243998C142724271 @default.
• W2084243998 hasConceptScore W2084243998C159985019 @default.
• W2084243998 hasConceptScore W2084243998C178790620 @default.
• W2084243998 hasConceptScore W2084243998C185592680 @default.
• W2084243998 hasConceptScore W2084243998C188027245 @default.
• W2084243998 hasConceptScore W2084243998C192562407 @default.
• W2084243998 hasConceptScore W2084243998C203036418 @default.
• W2084243998 hasConceptScore W2084243998C2779015675 @default.
• W2084243998 hasConceptScore W2084243998C2780742167 @default.
• W2084243998 hasConceptScore W2084243998C28845197 @default.
• W2084243998 hasConceptScore W2084243998C43617362 @default.
• W2084243998 hasConceptScore W2084243998C71924100 @default.
• W2084243998 hasConceptScore W2084243998C77281830 @default.
• W2084243998 hasConceptScore W2084243998C84199377 @default.
• W2084243998 hasConceptScore W2084243998C88380143 @default.
• W2084243998 hasIssue "1-2" @default.
• W2084243998 hasLocation W20842439981 @default.
• W2084243998 hasLocation W20842439982 @default.
• W2084243998 hasOpenAccess W2084243998 @default.
• W2084243998 hasPrimaryLocation W20842439981 @default.
• W2084243998 hasRelatedWork W1964085724 @default.
• W2084243998 hasRelatedWork W1987669606 @default.
• W2084243998 hasRelatedWork W2008242626 @default.
• W2084243998 hasRelatedWork W2084243998 @default.
• W2084243998 hasRelatedWork W2169796533 @default.
• W2084243998 hasRelatedWork W2312869912 @default.
• W2084243998 hasRelatedWork W2325167438 @default.
• W2084243998 hasRelatedWork W2971332222 @default.

• next